Elliott, Sarah T. C.
Kallewaard, Nicole L.
Benjamin, Ebony
Wachter-Rosati, Leslie
McAuliffe, Josephine M.
Patel, Ami
Smith, Trevor R. F.
Schultheis, Katherine http://orcid.org/0000-0001-9232-1888
Park, Daniel H.
Flingai, Seleeke
Wise, Megan C.
Mendoza, Janess
Ramos, Stephanie
Broderick, Kate E.
Yan, Jian
Humeau, Laurent M.
Sardesai, Niranjan Y.
Muthumani, Kar
Zhu, Qing
Weiner, David B.
Article History
Received: 9 February 2017
Revised: 17 May 2017
Accepted: 24 May 2017
First Online: 6 July 2017
Competing interests
: K.M. reports receiving grants from DARPA and Inovio, receiving consulting fees from Inovio related to DNA vaccine development, and a pending patent application (to Inovio) for delivery of DNA-encoded monoclonal antibodies. T.R.F.S., K.S., J.M., S.R., K.E.B., J.Y., L.M.H., N.Y.S. are employees of Inovio Pharmaceuticals and as such receive salary and benefits, including ownership of stock and stock option, from the company. D.B.W. has received grant funding, participates in industry collaborations, has received speaking honoraria, and has received fees for consulting, including serving on scientific review committees and board services. Remuneration received by D.B.W. includes direct payments or stock or stock options, and in the interest of disclosure he notes potential conflicts associated with this work with Inovio and possibly others. In addition, he has a patent DNA vaccine delivery pending to Inovio. N.L.K., E.B., L.W., J.M.M., Q.Z. are employees of MedImmune/AstraZeneca and may own stock in the company.